ImmVirX reports on operations for FY25
Melbourne, Australia 18 September 2025 – ImmVirX Pty Limited, a life sciences company dedicated to pioneering the next generation of receptor-targeted immunotherapies for patients confronted with common yet formidable cancers, is pleased to provide a summary of its operations for the financial year ended 30 June 2025. Over the past year, ImmVirX has made significant […]
